These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3599319)

  • 41. Antiviral therapeutic intervention in poliomyelitis-like syndrome.
    Arya SC
    Brain Dev; 1999 Dec; 21(8):567; author reply 568. PubMed ID: 10598062
    [No Abstract]   [Full Text] [Related]  

  • 42. Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014.
    Shaghaghi M; Shahmahmoodi S; Abolhassani H; Soleyman-Jahi S; Parvaneh L; Mahmoudi S; Chavoshzadeh Z; Yazdani R; Zahraei SM; Ebrahimi M; Eslamian MH; Tabatabaie H; Yousefi M; Kandelousi YM; Oujaghlou A; Rezaei N; Aghamohammadi A
    Emerg Infect Dis; 2016 Oct; 22(10):1712-9. PubMed ID: 27648512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Childhood immunizations: position on the enhanced inactivated poliovirus vaccine and live attenuated oral poliovirus vaccine dilemma.
    Willis E; Sherrod JL
    J Natl Med Assoc; 1997 Dec; 89(12):785-9. PubMed ID: 9433057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination-induced poliomyelitis in Idaho; preliminary report of experience with Salk poliomyelitis vaccine.
    PETERSON LJ; BENSON WW; GRAEBER FO
    J Am Med Assoc; 1955 Sep; 159(4):241-4. PubMed ID: 13251869
    [No Abstract]   [Full Text] [Related]  

  • 46. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine.
    Abraham R; Minor P; Dunn G; Modlin JF; Ogra PL
    J Infect Dis; 1993 Nov; 168(5):1105-9. PubMed ID: 8228342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. sIPV process development for costs reduction.
    Thomassen YE; Bakker WA
    Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Prevots DR; Burr RK; Sutter RW; Murphy TV;
    MMWR Recomm Rep; 2000 May; 49(RR-5):1-22; quiz CE1-7. PubMed ID: 15580728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Poliomyelitis in the USA: virtual elimination of disease caused by wild virus.
    Kim-Farley RJ; Bart KJ; Schonberger LB; Orenstein WA; Nkowane BM; Hinman AR; Kew OM; Hatch MH; Kaplan JE
    Lancet; 1984 Dec; 2(8415):1315-7. PubMed ID: 6150330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper.
    Wkly Epidemiol Rec; 2010 Jun; 85(23):213-28. PubMed ID: 20545051
    [No Abstract]   [Full Text] [Related]  

  • 52. [Anti-poliomyelitis vaccination].
    Cadrobbi P
    G Mal Infett Parassit; 1970 Apr; 22(4):273-8. PubMed ID: 5515865
    [No Abstract]   [Full Text] [Related]  

  • 53. Planning of polio vaccination campaigns.
    Squarcione S
    Lancet; 1996 Nov; 348(9039):1454. PubMed ID: 8937305
    [No Abstract]   [Full Text] [Related]  

  • 54. Poliovirus antibody differentiation. Methods and application for strain specific diagnosis in complications after oral vaccination.
    Kuwert E; Höher PG; Thraenhart O
    Zentralbl Bakteriol Orig A; 1976 Apr; 234(3):407-12. PubMed ID: 180727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The final phase of polio eradication: new vaccines and complex choices.
    Cochi SL; Linkins RW
    J Infect Dis; 2012 Jan; 205(2):169-71. PubMed ID: 22158681
    [No Abstract]   [Full Text] [Related]  

  • 56. [VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS IN RUSSIAN FEDERATION DURING THE PERIOD OF CHANGES IN VACCINATION SCHEDULE (2006-2013 yy.)].
    Ivanova OE; Eremeeva TP; Morozova NS; Shakaryan AK; Gmyl AP; Yakovenko ML; Korotkova EA; Chernjavskaja OP; Baykova OY; Silenova OV; Krasota AY; Krasnoproshina LI; Mustafina AN; Kozlovskaja LI
    Vopr Virusol; 2016; 61(1):9-15. PubMed ID: 27145594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Poliomyelitis vaccines.
    S Afr Med J; 1977 Nov; 52(22):868. PubMed ID: 607496
    [No Abstract]   [Full Text] [Related]  

  • 58. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antigenic hybrids of poliovirus.
    Hogle JM
    Nature; 1988 Mar; 332(6159):13-4. PubMed ID: 2831454
    [No Abstract]   [Full Text] [Related]  

  • 60. The polio endgame.
    Minor P
    Hum Vaccin Immunother; 2014; 10(7):2106-8. PubMed ID: 25608050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.